|1.||Gawad, Yehia: 2 articles (01/2005 - 11/2002)|
|2.||Rouleau, Jean L: 2 articles (01/2005 - 11/2002)|
|3.||Stanton, Eric B: 2 articles (01/2005 - 11/2002)|
|4.||Hansen, Mark S: 2 articles (01/2005 - 11/2002)|
|5.||Swedberg, Karl: 2 articles (01/2005 - 11/2002)|
|6.||Packer, Milton: 2 articles (01/2005 - 11/2002)|
|7.||Pitt, Bertram: 2 articles (01/2005 - 11/2002)|
|8.||Echizen, Hirotoshi: 1 article (12/2014)|
|9.||Stachnik, Joan M: 1 article (12/2014)|
|10.||Ogawa, Ryuichi: 1 article (12/2014)|
03/01/1991 - "Flosequinan (F) is a potent vasodilator and produces hemodynamic improvement when given to patients (pts) with congestive heart failure (CHF) but little is known about its direct effect on the regional pulmonary vascular bed. "
09/01/1998 - "Thus flosequinan exerted not only positive inotropic but also positive lusitropic effects, in association with a significant reduction of both pulsatile and steady components of LV afterload, contributing to an improvement of LV-pump function in acute cardiac failure."
12/01/1992 - "Flosequinan therapy in patients with congestive heart failure results in a sustained beneficial hemodynamic action and improved cardiac performance without an increase in metabolic demand or activation of the sympathetic nervous system."
02/18/1992 - "The high inhibitory concentrations observed (IC50 peak III 660 microM for cardiac tissue and 230 microM for vascular smooth muscle with flosequinan) relative to its clinically effective plasma concentration (10 microM) questions the relevance of phosphodiesterase inhibition to the efficacy of flosequinan in heart failure."
03/01/1991 - "Flosequinan has the advantage of being able to relax both arterial and venous beds and as such may be particularly beneficial in the treatment of heart failure."
09/01/1989 - "We conclude that flosequinan is effective in producing acute hemodynamic improvement in patients with heart failure complicating acute myocardial infarction which is resistant to conventional therapy. "
07/01/1989 - "We conclude that flosequinan is effective in producing acute hemodynamic improvement in patients with heart failure, complicating acute myocardial infarction, which is resistant to conventional therapy. "
08/01/1988 - "We concluded that flosequinan can produce acute hemodynamic improvement in patients with heart failure, complicating acute myocardial infarction. "
08/01/1988 - "Flosequinan induces hemodynamic improvement in heart failure complicating acute myocardial infarction."
09/01/1989 - "The effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction."
07/01/1996 - "With a dose of 75 mg twice daily, heart rates under these conditions increased by >20 beats/min in flosequinan-treated patients in atrial fibrillation, a change significantly greater than that observed with placebo or flosequinan, 100 mg once daily and also more than in patients in sinus rhythm treated with the same dose. "
07/01/1996 - "These results indicate that flosequinan facilitates atrioventricular nodal conduction, increasing the ventricular response in atrial fibrillation, especially at higher dosages. "
07/01/1996 - "Flosequinan increased heart rate in a dose-dependent manner, in patients both with sinus rhythm and atrial fibrillation. "
07/01/1996 - "The effects of two doses of flosequinan on supine, standing, ambulatory, and exercise heart rates and on exercise capacity in patients in sinus rhythm and atrial fibrillation were compared. "
07/01/1996 - "This study evaluated the effects of flosequinan on ventricular rate in patients with congestive heart failure and atrial fibrillation to determine whether this agent has a facilitatory effect on atrioventricular conduction and whether such an effect may be deleterious. "
|4.||Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
07/01/1994 - "These data indicate that when flosequinan, a new therapeutic agent for the treatment of congestive heart failure, is administered in hemodynamically relevant low doses to patients with dilated congestive cardiomyopathy who were receiving standard therapy for heart failure, left ventricular pump function and diastolic function is further improved. "
03/01/1991 - "Data generated from animal studies indicate that flosequinan produces dilatation in both veins and arteries, with little associated reflex tachycardia. "
05/01/1995 - "Flosequinan (BTS 49465, 7-fluoro-1-methyl-3-methyl-sulphinyl-4-quinolone), a recently direct-acting vasodilator that should cause relatively less reflex tachycardia, was given in a single oral dose of 200 mg to 10 untreated patients with moderate to severe hypertension. "
06/01/1988 - "5. The lesser degree of tachycardia and increase in plasma renin activity together with a lack of sodium retaining activity associated with flosequinan suggest that this agent may have potential advantages over existing therapy as an antihypertensive in man."
06/01/1988 - "2. The degree of tachycardia and increase in plasma renin activity (PRA) for equivalent falls in mean blood pressure in both species was significantly less for flosequinan than for hydralazine (P less than 0.05). "
|6.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)